Singapore markets close in 48 minutes

Ironwood Pharmaceuticals, Inc. (IRWD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.14-0.06 (-0.54%)
At close: 04:00PM EST
11.14 0.00 (0.00%)
After hours: 04:14PM EST
Full screen
Trade prices are not sourced from all markets
Previous close11.20
Open11.05
Bid0.00 x 900
Ask0.00 x 1800
Day's range10.84 - 11.23
52-week range8.78 - 14.27
Volume1,877,814
Avg. volume2,223,649
Market cap1.823B
Beta (5Y monthly)1.21
PE ratio (TTM)3.43
EPS (TTM)3.25
Earnings date15 Feb 2022 - 21 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.00
  • Business Wire

    Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance

    BOSTON, January 10, 2022--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2021 and announced financial guidance for full year 2022. The results were announced in advance of the Company’s presentation at the 40th Annual J.P. Morgan Healthcare Conference, which will take place on Wednesday, January 12, 2022 at 7:30 a.m. ET.

  • Business Wire

    Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

    BOSTON, January 05, 2022--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. ET.

  • Business Wire

    Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

    BOSTON, December 01, 2021--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood’s Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive offi